Kennedy, a longtime pharma critic, embraces Trump deal to expand access to obesity drugs

What's new in pharma

November 7, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

STAT+ | Kennedy, a longtime pharma critic, embraces Trump deal to expand access to obesity drugs RFK Jr. calls expanded availability of obesity drugs a tool against chronic disease. Some MAHA followers wonder if movement has lost its way By Isabella Cueto STAT+ | Why one expert thinks Gilead can produce a $25 HIV prevention shot, help eradicate the disease in the U.S. Andrew Hill, University of Liverpool professor, says Gilead's HIV preventive Yetzugo could be produced at scale for $25. Current price is $28,000. By Ed Silverman Opinion: Modern animal models for biomedical research remain far better than alternatives Biomedical discovery and drug development require greater investment in refining and complementing, not replacing, animal models. By Anis Barmada Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser